WO2005014803A1 - Vaccin contre le virus du nil occidental - Google Patents

Vaccin contre le virus du nil occidental Download PDF

Info

Publication number
WO2005014803A1
WO2005014803A1 PCT/JP2004/011041 JP2004011041W WO2005014803A1 WO 2005014803 A1 WO2005014803 A1 WO 2005014803A1 JP 2004011041 W JP2004011041 W JP 2004011041W WO 2005014803 A1 WO2005014803 A1 WO 2005014803A1
Authority
WO
WIPO (PCT)
Prior art keywords
west nile
nile virus
wnv
virus
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2004/011041
Other languages
English (en)
Japanese (ja)
Inventor
Kengo Sonoda
Yuji Ishikawa
Kiyoto Nishiyama
Shoji Kuzuhara
Yoichiro Kino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemo Sero Therapeutic Research Institute Kaketsuken
Original Assignee
Chemo Sero Therapeutic Research Institute Kaketsuken
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemo Sero Therapeutic Research Institute Kaketsuken filed Critical Chemo Sero Therapeutic Research Institute Kaketsuken
Publication of WO2005014803A1 publication Critical patent/WO2005014803A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24164—Methods of inactivation or attenuation by serial passage
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to a West Nile virus (hereinafter sometimes referred to as “WNV”) vaccine.
  • WNV-infected cells obtained by culturing cell lines (Vero cells) derived from the kidney of African green lantern seeded with WNV, or a culture solution thereof.
  • a method for highly purifying WNV which is obtained by the method.
  • the present invention relates to WNV and a vaccine containing the WNV or an antigen component thereof.
  • West Nile virus is a single-stranded RNA virus having a diameter of about 50 nm and belonging to the Flaviviridae family, which uses birds such as crows, pigeons and sparrows as natural hosts. WNV also infects pests and humans through the transmission of mosquitoes, such as the Koga takae power, which breeds in paddy fields, the mosquito power that lives in urban areas, and the Aedes albopictus power. In the case of infectious diseases caused by the Japanese encephalitis virus (QEV) belonging to the same flaviviridae family, the mosquitoes that carry JEV are almost limited to the mosquito mosquitoes. Because they are transmitted by various mosquitoes, they are widespread, including in urban areas.
  • QEV Japanese encephalitis virus
  • WNV was first isolated from a febrile patient in Kenya in 1937. WNV infection has spread in Egypt, Israel, France, South Africa, and elsewhere since the 1950s, and has spread to African countries, the Middle East, Asia, and Europe since 1994. Outbreaks in four states on the mainland in 1999 resulted in 62 cases of infection. Mosquito control by spraying insecticides, etc., has reduced the number of infected people, but it has not been able to control the activity of the virus. confirmed. The epidemic of the year ultimately resulted in 284 deaths out of 4,156 infected individuals. Vaccines for pests against WNV infection have already been developed, and none have been developed for humans, which has greatly contributed to the prevention of infectious diseases. At present, WNV infection is prevented indirectly by mosquito control, and the development of an effective vaccine is urgently needed.
  • WNV is directly used as a vaccine material.
  • a live vaccine attenuated by passage of WNV with mosquito cells was effective against geese (see Non-Patent Document 1). It has been reported that WNV obtained from human brain was inactivated with formalin and administered with oil adjuvant, and then WNV challenge test showed 52-80% efficacy (see Non-Patent Document 2). I have.
  • vaccines that use infected mouse brain emulsion as a starting material may cause allergic central nervous system damage or contamination with pathogenic microorganisms due to contaminants derived from mouse brain. It has been pointed out that the use of animals is becoming difficult, and the production cost is high. In addition, the use of animals must be avoided as much as possible from the viewpoint of animal welfare. For live attenuated vaccines, a long-term vaccine effect can be expected, but there is concern that the pathogenicity may be restored by mutation.
  • flaviviridae viruses include a coat glycoprotein called E protein, which is a major infection-protecting antigen common to flaviviruses, and the potential of WNV vaccines using these proteins is also being studied.
  • E protein a coat glycoprotein
  • M. Malkinson and colleagues have confirmed that gooses have some WNV protective effects with a commercial vaccine derived from the Israeli Turkey Meningoencephalitis (TME) virus.
  • TME Israeli Turkey Meningoencephalitis
  • Non-patent document 1 S. Lustig et al, Viral Immunology, 13, 4, p.401-10 (2000)
  • Non-Patent Document 2 M. Malkinson et al., New York Academy of Sciences, 951, p.255-61 (2001)
  • Non-Patent Document 3 R.B.Tesh et al., Infectious Disease, 8, 3, p.245-51 (2002)
  • Non-Patent Document 4 N. Kanesa-Thasan et al, American Journal of Tropical Medicine and
  • Non-patent document 5 T. Wang et al., Journal of Immunology, 167, 9, p. 5273-7 (2001)
  • Non-patent document 6 JS Yang et al., Journal of Infectious Disease, 184, 7, p. 809-16 (2001)
  • Non-Patent Document 7 BS Davis et al, Journal of Virology, 75, 9, p. 4040-7 (2001)
  • Non-Noon Document 8 AG Pletnev et al., Proceeding of National Academy of Sciences USA, 99, 5, p. .3036-41 (2002)
  • an object of the present invention is to provide a highly purified WNV, a method for producing a WNV actin using the purified WNV, and a WNV vaccine produced by the method.
  • WNV was inoculated into Vero cells adhered to microcarriers and cultured at a high density, and this was inoculated with serum-free serum for virus culture.
  • Medium We found that WNV was produced in extremely large amounts by culturing under appropriate culture conditions in VP-SFM. In addition, this WNV was completely inactivated by formalin, and the inactivated WNV was highly purified by sucrose density gradient centrifugation and, optionally, further column chromatography.
  • the inactivated vaccine prepared using purified WNV was found to induce antibodies having high neutralizing ability against WNV and related Japanese encephalitis virus, and completed the present invention.
  • the present invention provides a method of inoculating WNV into Vero italocytes adhered to microcarriers and cultured at high density, and culturing them in a serum-free medium for virus culture VP-SFM under appropriate culture conditions. And a method for producing a purified and inactivated WNV, which comprises a step of inactivating the obtained virus solution with formalin, and purifying the virus solution by sucrose density gradient centrifugation, and optionally column chromatography. [0014] The present invention also includes purified and inactivated WNV highly purified by the above-mentioned production method and having a neutralizing activity against WNV and Japanese encephalitis virus.
  • a highly purified inactivated WNV and a method for producing the same are provided.
  • a serum-free, low-concentration protein medium is used to reduce the amount of impurity protein to be removed from the culture solution during virus growth.
  • the purification step can be simplified, so that the production time can be reduced, the yield of WNV can be improved, and high-purity WNV can be obtained. This will enable low cost, mass production and stable supply of WNV vaccines.
  • a serum-free medium since a serum-free medium is used, the possibility of contamination with unknown pathogens derived from serum can be reduced.
  • the purified and inactivated WNV of the present invention since the purified and inactivated WNV of the present invention has an ability to induce a neutralizing antibody against both WNV and Japanese encephalitis virus, it protects not only infections caused by WNV but also infections caused by Japanese encephalitis virus. It can be used as a vaccine with the efficacy of BEST MODE FOR CARRYING OUT THE INVENTION
  • the present invention provides (1) a step of inoculating WNV into Vero cells attached to a microcarrier and culturing it at a high density, (2) a step of inactivating WNV with formalin, and (3) a sucrose gradient.
  • the present invention relates to a method for producing purified inactivated WNV, which further comprises a step of optionally purifying WNV by column chromatography, and a purified inactivated WNV obtained by the production method.
  • the WNV used in the present invention a clinical isolate can be used, but the type of the strain is not particularly limited.
  • the CDC Centers for Disease Control
  • EglOl hereinafter, also referred to as “EG strain”
  • NY99-35262-ll hereinafter sometimes referred to as “NY stock”.
  • any animal cell can be used as long as it is an animal cell in which WNV is grown.
  • a host cell for obtaining a high-concentration virus solution is used. It is preferable to use a cell line that allows density culture.
  • Such cell lines include Vero cells, CHO cells, MDCK cells and the like. Preferably, Vero cells are used.
  • a medium used for growing Vero cells a commercially available medium generally used for tissue culture, such as an Ml99 medium or an Eagle MEM medium, may be prepared according to the attached use method.
  • a serum-free, low-concentration protein medium that does not contain animal serum.
  • VP-SFM GIBC II
  • EX-CELL series Nichirei
  • SFM-101 SFM-101 (Nissi), etc.
  • the pH of the medium is adjusted to 78, preferably 7.4, suitable for growing animal cells.
  • microcarriers for attaching Vero cells various types of microbeads having different types such as size, shape, density, surface charge, and surface coat material are commercially available. And use it.
  • microbeads such as Cytodex I (Cytodex I, Amersham Bioscience), Biosilon (Nargennuk International), and CELLYARD (Pentax) are preferred.
  • the amount of the cytodettas used is 1 to 10 g, preferably 3 to 5 g, per liter of the culture solution.
  • High-density culturing is achieved by culturing cells adhered to the microcarrier in a fermenter by the Fedo batch method.
  • Vero cells To attach Vero cells to cytodettas, put the cytodettas and the above-mentioned culture solution into a fermenter so that the concentration becomes 3 g / L, add 15 ⁇ 10 8 cells to this, and add the culture solution at a speed of 20 40 rpm. Is cultured while rotating and agitating, and the Itoda cells are allowed to adhere to cytodettas and proliferate.
  • the cultivation temperature and cultivation period are controlled by a combination of the number of cells to be attached, the culture scale, etc.
  • the cultivation temperature is 32 to 38 ° C, and the cultivation period is 2 to 7 days.
  • WNV inoculation is performed after the growth of Vero cells reaches a stable period.
  • the medium is aspirated off, and cells without serum or cells washed several times with phosphate buffered saline are inoculated with a viral load of 0.01 0.0001 (MOI).
  • Culture of virus-infected cells Cultivation is performed at 32-38 ° C for 115 days using a VP-SFM medium supplemented with L-glutamic acid.
  • the cells are cultured at 37 ° C for 2-3 days.
  • For the pH drop and nutrient deficiency that occur during the culture period add 2 to 10%, preferably 6% glucose, 10 to 20%, preferably 15% sodium carbonate solution as needed by the Fued-batch method.
  • no-nores contains an extremely high concentration of virus.
  • the above-mentioned virus stock solution is concentrated with an ultrafiltration membrane having an exclusion limit molecular weight of 100,000 to 500,000, preferably 30.500,000, and a final concentration of 0.02 0.1% This is done by adding formalin to the soy sauce and leaving it at about 4 ° C for 11 months.
  • the inactivation may be performed on the virus solution during or after purification. Completion of the inactivation is confirmed by inoculating a part of the inactivated virus stock solution into Vero cells, culturing the cells, and observing the presence or absence of virus growth.
  • the virus stock solution after the inactivation treatment is purified by sucrose density gradient centrifugation at 20,000-50,000 rpm for 2-24 hours. Preferably, sucrose density gradient centrifugation at 30,000 rpm for 16 hours is performed.
  • the virus-containing fraction thus obtained is highly purified, and is desalted by ultrafiltration or dialysis, or diluted with an appropriate buffer, and then sterile-filtered with a membrane filter to obtain the vaccine starting material.
  • Used as The vaccine raw materials include immunostimulants such as aluminum hydroxide, aluminum phosphate, mineral oil and non-mineral oil, stabilizers such as polysorbate 80, sugars such as amino acids and ratatose sucrose, and formalin, thimerosal, and 2-phenoki.
  • Formulation is carried out by appropriately selecting and adding a preservative such as ciethanol, benzyl alcohol, benzethonium chloride, and salt of benzenikonium.
  • a preservative such as ciethanol, benzyl alcohol, benzethonium chloride, and salt of benzenikonium.
  • a sugar such as ratatose or sucrose having an effect as an excipient is added, it can be formulated as a lyophilized preparation.
  • the virus-containing fraction after the above sucrose density gradient centrifugation is further purified by column chromatography depending on the purpose of use.
  • column chromatography include cation chromatography, anion chromatography, and adsorption chromatography, which are generally used for purification of proteins and polypeptides.
  • WNV granules Cellulose sulfate gel which can purify the particles with high purity is used.
  • Efficacy as a vaccine can be determined by inoculating an animal with the vaccine and conducting an challenge test or by measuring the virus neutralizing ability of the serum of the vaccinated animal. More specifically, mice are immunized with a suitably diluted WNV vaccine solution to produce antibodies against WNV. The effectiveness of the antibody as a vaccine can be examined by measuring the neutralizing activity of this antibody by the 50% plaque reduction method.
  • the method of immunization of a mouse may be a commonly used immunization method. For example, an immune serum is obtained by booster injection 13 to 13 weeks after the first vaccination with WNV vaccine, blood sampling 1 week after the booster vaccination, and serum separation.
  • the vaccine obtained according to the present invention not only induces a neutralizing antibody against W NV but also can induce a neutralizing antibody against Japanese encephalitis virus.
  • Vaccine According to a report by Ben-Nathan D et al. (J. Infect. Dis., 2003 Jul. 1; 188 (1), 5_12), it is clear that antibodies play an important role in the treatment and prevention of WNV infection. It has been suggested that the WNV vaccine of the present invention is extremely effective in preventing WNV infection. In addition, the vaccine of the present invention is expected to be a more effective vaccine when mixed with a vaccine derived from another W NV strain, for example, an EG strain.
  • At least one vaccine selected from the group consisting of vaccines against other viruses (eg, Japanese encephalitis virus, hepatitis A virus, rabies virus) and bacteria (eg, pertussis and diphtheria 'tetanus bacteria). By combining them, they can be used as a combination vaccine.
  • viruses eg, Japanese encephalitis virus, hepatitis A virus, rabies virus
  • bacteria eg, pertussis and diphtheria 'tetanus bacteria.
  • Vero cells (CCL-81 strain) purchased from ATCC were used as cell lines for virus propagation. This was suspended in M199 medium containing 10% serum and cultured in a 5% CO 2 incubator at 37 ° C. for 5-7 days. The obtained cells were stored as a cell bank. Cells were grown up to the tank culture using Dulbecco's MEM medium containing 5% Under the same conditions. For tank cultivation, use a 5 liter fermentation tank. Add 5 x 10 8 Vero cells and 15 g of cytodetase to 5 L of Dulbecco's MEM medium containing 5% serum, and add 3 to 7 at 37 ° C and 40 rpm. Cultured for days. This culture yields 1 ⁇ 10 6 or more cells per mL.
  • the cells attached to the cytodettas were washed with serum-free Dulbecco's MEM to remove serum and other cell metabolites generated during cell culture, and then infected with VP-S FM medium to an infection efficiency of 0.01%.
  • One liter of a WNV solution adjusted to be 1 was added, and the culture was continued.
  • the cells were cultured at 37 ° C. and a rotation speed of 20 rpm for 90 minutes.
  • the rotation speed was increased to 40 rpm, and the culture was continued while maintaining the dissolved oxygen content of 2 ppm.
  • the pH during the culture was maintained at 7.4 by adding a 15% sodium carbonate solution containing 6% gnorecose (Glu) as needed.
  • the culture solution was collected, and the virus content was measured by the plaque assay.
  • Table 1 shows the relationship between the above pH maintenance and the presence or absence of glucose addition and the virus content in the medium. Numerical values indicate virus production (nLoglO).
  • the harvested virus solution was subjected to coarse centrifugation at 3,000 rpm for 5 minutes to remove cytodotes and cells, and then concentrated to 10 to 30 times using an ultrafiltration membrane (exclusion limit molecular weight: 300,000).
  • SARTOCON SLICE DISPORSABLE Fuji filter
  • Formalin was added to the concentrated solution to a concentration of 0.08% and left at 4 ° C for 70-120 days to inactivate the virus.
  • virus particles were purified by sucrose density gradient centrifugation.
  • Rotor PR42 (Hitachi) was used, and 10-30 mL of 50% sucrose solution, 10-30 mL of 30% sucrose solution, and 10-30 mL of virus-inactivated sample solution were sequentially layered on a centrifuge tube, and then 30,000 rpm, 4 Centrifugation was performed at ° C for 16 hours. After centrifugation, sucrose concentration 40 at which OD280 absorbance is observed. Fractions lOOmL above / o were pooled. Then, after dialysis in 10 L of phosphate buffer at 4 ° C. for 1 day, the solution was sterile filtered to obtain a purified inactivated antigen. This was diluted with phosphate buffered saline so as to contain a protein amount of 30 zg / mL, and polysonolate 80 was added to this at a concentration of 0.01% to prepare a prototype vaccine.
  • a part of the purified inactivated antigen obtained by the sucrose density gradient ultracentrifugation was dialyzed against a buffer having a pH shown in Table 2 below. The same buffer was applied to a column filled with sulfated cell mouth fines. After washing with the same buffer, elution was carried out with the same buffer containing 0-3 M sodium chloride. The recovery was calculated from the absorbance of the eluted fraction and the liquid volume.
  • the purified inactivated antigen obtained by additional purification by column chromatography as described above was diluted with phosphate-buffered saline to contain a protein amount of 30 zg / mL, and polysorbate 80 was added thereto.
  • the prototype vaccine was added to make it 01%.
  • DNA extractor kit (Wako) was used for nucleic acid extraction from the specimen.
  • the obtained nucleic acid is converted to Biodot SF ( Bio-Rad), followed by hybridization with Vero cell-derived DNA labeled with the Gene Image Labeling System (Amersham Pharmacia Biotech), followed by Gene Image Detection Kit (Amersham). (Pharmacia Biotech).
  • the signal from chemiluminescence was quantified, and the amount of nucleic acid in the sample was determined using the standard sample as a standard. A known amount of Vero cell-derived nucleic acid was used as a standard sample.
  • the detection limit was 6.72 pg / mL, and the relative reproducibility was 37.04%.
  • the content of DNA derived from the host was less than lng per inoculum (15 ⁇ g of protein) before purification by chromatography, and less than lOOpg after purification by chromatography.
  • the protein obtained from the culture supernatant of Vero cells was immunized to rabbits and guinea pigs to prepare anti-Vero protein antibodies.
  • the anti-Vero protein guinea pig antibody was adsorbed to a 96-well plate (Nunc) at 500 ng / well, and an appropriately diluted prototype vaccine solution was added thereto, followed by incubation at 37 ° C for 2 hours. Next, add anti-Vero protein / sagi antibody in 100 ng / well and incubate at 37 ° C for 2 hours. And developed the color.
  • the protein amount was determined from a calibration curve created using known amounts of Vero protein.
  • the quantitation limit was 2.284 ng / mL, and the relative reproducibility was 8.84%. As a result, as shown in Table 4, it was shown that the amount was less than 100 ng per inoculation amount (protein amount: 15 zg).
  • test vaccine solution is used as it is or diluted 4-fold with phosphate-buffered saline, and inoculated in the abdominal cavity of ddY mouse (female, 4-week-old) in 0.5 mL aliquots into 20 mice, and boosted with the same volume one week later After one week, blood was collected and serum separated.
  • the neutralized antibody titer of the obtained serum was measured by a 50% plaque reduction method using Vero cells.
  • Vero cells As a control, Japanese encephalitis vaccine immune serum was used. Table 5 shows the results.
  • ddY mice (SPF, 3w female) were purchased from SLC Japan and used. After acclimation for about one week, the vaccines shown in Table 6 below were diluted 4-fold with PBS, and 0.5 mL was intraperitoneally administered twice a week at an interval of one week. One week after the administration, the WNV-NY99 strain was intraperitoneally administered with the dose shown in Table 6 below using the JEV Beijing strain as an aggressive virus, followed by observation for two weeks.
  • Table 6 shows the results after two weeks. The number is the number of surviving mice / number of test mice.
  • WNV was used as the challenge virus
  • most of the non-immunized mouse groups developed and died.
  • the JEV vaccine-administered group partially died of onset, which resulted in death, but there were some individuals who lost their energies, indicating that the protective effect of the JEV vaccine against WNV attack was partial. Indicated.
  • the WNV-NY strain vaccine showed perfect protection at all doses, with no transient deprivation.
  • JEV was used as the aggressive virus, half of the non-immunized mouse group developed part of the mice and died.
  • the JEV vaccine-administered group showed almost perfect protection against onset.
  • W NV—NY strain vaccine showed perfect protection.
  • the JEV vaccine is effective against JEV, but its efficacy against WNV is partial and insufficient.
  • the WNV vaccine did not show any transient desensitization or onset to WNV or JEV, indicating a complete protective effect.
  • the inactivated West Nile virus (WNV) obtained by the method of the present invention is highly purified and has a neutralizing activity against WNV and Japanese encephalitis virus. It can be used as an antigen material for vaccines against WNV and Japanese encephalitis virus infection by using it together with immunostimulants, dispersants, stabilizers, preservatives and the like.
  • the WNV of the present invention is used as an antigen for producing monoclonal antibodies and polyclonal antibodies, or as a research material relating to the binding of an anti-WNV antibody to WNV, for example, a detection system material such as ELISA and WB. Available.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un procédé pour produire un vaccin contre le virus du Nil occidental (West Nile Virus : WNV) et un vaccin contre le WNV atténué produit selon ce procédé. Ce procédé consiste à mettre en culture une lignée cellulaire établie (cellules Véro) provenant du rein d'un singe vervet auquel on a inoculé le WNV avec une grande densité, à atténuer les cellules infectées par le WNV ou un milieu de culture liquide de celles-ci ainsi obtenu, puis à purifier de façon importante le WNV par centrifugation sur gradient de sucrose. La présente invention concerne également le WNV obtenu selon ce procédé, ainsi qu'un vaccin contre le WNV atténué comprenant le WNV ou un composant antigénique de celui-ci qui est le composant principal et est sensiblement exempt d'acides nucléiques ou de protéines provenant de l'hôte.
PCT/JP2004/011041 2003-08-07 2004-08-02 Vaccin contre le virus du nil occidental Ceased WO2005014803A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003-288820 2003-08-07
JP2003288820A JP2007068401A (ja) 2003-08-07 2003-08-07 西ナイルウイルスワクチン

Publications (1)

Publication Number Publication Date
WO2005014803A1 true WO2005014803A1 (fr) 2005-02-17

Family

ID=34131530

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2004/011041 Ceased WO2005014803A1 (fr) 2003-08-07 2004-08-02 Vaccin contre le virus du nil occidental

Country Status (2)

Country Link
JP (1) JP2007068401A (fr)
WO (1) WO2005014803A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008104450A (ja) * 2006-09-29 2008-05-08 Osaka Industrial Promotion Organization 高病原性トリインフルエンザウイルスに対するモノクローナル抗体
KR101813017B1 (ko) 2008-08-29 2017-12-28 베링거잉겔하임베트메디카인코퍼레이티드 웨스트 나일 바이러스 백신
CN108434106A (zh) * 2017-04-25 2018-08-24 广州瑞贝斯药业有限公司 一种狂犬病疫苗的冻干制剂

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2687119C (fr) 2007-05-04 2021-06-08 Baxter International Inc. Formulation de solutions sucrees pour ultracentrifugation en continu pour purification de virus
JP5352578B2 (ja) * 2007-05-04 2013-11-27 バクスター・インターナショナル・インコーポレイテッド ウイルスの増殖のための二段階温度プロフィール
KR102482744B1 (ko) 2016-11-04 2022-12-30 다케다 야쿠힌 고교 가부시키가이샤 아데노-연관 바이러스 정제 방법
JP6777837B1 (ja) * 2020-02-10 2020-10-28 花王株式会社 ヒトノロウイルス不活化評価法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5048118A (fr) * 1973-08-29 1975-04-30
JPH02223531A (ja) * 1988-11-10 1990-09-05 Takeda Chem Ind Ltd 日本脳炎ワクチンの製造法
JPH05502581A (ja) * 1989-12-22 1993-05-13 イムノ・アクチエンゲゼルシャフト 付着的に結合した細胞を有するマトリックスおよびウイルス／ウイルス抗原の製造方法
JP2001514844A (ja) * 1997-08-28 2001-09-18 シェイル、ジェダン、コーポレーション ベロ細胞に適応させた弱毒化日本脳炎ウィルスおよび日本脳炎ワクチン
JP2003523169A (ja) * 1998-12-31 2003-08-05 アバンテイス・フアルマ・エス・アー ウイルス粒子の分離法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5048118A (fr) * 1973-08-29 1975-04-30
JPH02223531A (ja) * 1988-11-10 1990-09-05 Takeda Chem Ind Ltd 日本脳炎ワクチンの製造法
JPH05502581A (ja) * 1989-12-22 1993-05-13 イムノ・アクチエンゲゼルシャフト 付着的に結合した細胞を有するマトリックスおよびウイルス／ウイルス抗原の製造方法
JP2001514844A (ja) * 1997-08-28 2001-09-18 シェイル、ジェダン、コーポレーション ベロ細胞に適応させた弱毒化日本脳炎ウィルスおよび日本脳炎ワクチン
JP2003523169A (ja) * 1998-12-31 2003-08-05 アバンテイス・フアルマ・エス・アー ウイルス粒子の分離法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BOROWSKI P. ET AL.: "Purification and characterization of West Nile virus nucleoside triphosphatase (NTPase)/helicase: evidence for dissociation of the NTPase and helicase activities of the enzyme", J. VIROL., vol. 75, no. 7, 2001, pages 3220 - 3229, XP002903498 *
DEBNATH N.C. ET AL.: "In vitro homotypic and heterotypic interference by defective interfering particles of West ile virus", J. GEN. VIROL., vol. 72, no. 11, 1991, pages 2705 - 2711, XP002903497 *
MORITA K.: "Nishi Nile netsu no vaccine", MED. TECHNOL., vol. 32, no. 4, 15 April 2004 (2004-04-15), pages 347 - 348, XP002985309 *
SHLOMO LUSTIG ET AL.: "A live attenuated West Nile virus strain as a potential veterinary vaccine", VIRAL IMMUNOLOGY, vol. 13, no. 4, 2000, pages 401 - 410, XP008018324 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008104450A (ja) * 2006-09-29 2008-05-08 Osaka Industrial Promotion Organization 高病原性トリインフルエンザウイルスに対するモノクローナル抗体
KR101813017B1 (ko) 2008-08-29 2017-12-28 베링거잉겔하임베트메디카인코퍼레이티드 웨스트 나일 바이러스 백신
CN108434106A (zh) * 2017-04-25 2018-08-24 广州瑞贝斯药业有限公司 一种狂犬病疫苗的冻干制剂

Also Published As

Publication number Publication date
JP2007068401A (ja) 2007-03-22

Similar Documents

Publication Publication Date Title
JP6896700B2 (ja) ワクチン組成物
JP6104988B2 (ja) アルミニウム不含アジュバントを添加した不活化デング熱ウイルスワクチン
ES2524975T3 (es) Cepa del virus de la fiebre amarilla de alto rendimiento con mayor propagación en células
CN112912106A (zh) 登革热疫苗单位剂量及其施用
US20240050557A1 (en) Coronavirus vaccine and method for preparation thereof
JP6985384B2 (ja) 弱毒変異型ジカウイルスを含むワクチン組成物
JPWO2019124557A1 (ja) 交差免疫抗原ワクチン及びその調製方法
JP2016523912A (ja) デングウイルスワクチンのための方法および組成物
RU2447898C2 (ru) Вакцина ipv-dpt
JP4751558B2 (ja) 日本脳炎不活化ワクチン及びその製造方法
WO2005014803A1 (fr) Vaccin contre le virus du nil occidental
WO2009004641A2 (fr) Adaptation de la souche pitman-moore de virus rabique à des cultures cellulaires de fibroblastes d'embryon de poulet primaires
CN107137703B (zh) 一种狂犬病免疫原性结合物和疫苗及其制备方法
CN109432413B (zh) 一种森林脑炎病毒灭活疫苗及其制备方法
EP2632487A2 (fr) Vaccin viral et son procédé de préparation
JP5946453B2 (ja) 変異狂犬病ウイルス及びワクチン
RU2665849C1 (ru) Вакцина инактивированная эмульсионная против ящура типа О
KR102365464B1 (ko) 지카바이러스 재조합 서브유닛 백신의 개발 및 이의 제조방법
Webster et al. Efficacy of equine influenza vaccines for protection against A/Equine/Jilin/89 (H3N8)—a new equine influenza virus
RU2631925C2 (ru) Штамм "Шевченко-2014" вируса геморрагической болезни кроликов для изготовления вакцинных, диагностических и лечебных препаратов
KR0123538B1 (ko) 한탄바이러스, 서울바이러스, 푸우말라바이러스, 벨그라드바이러스 및 호왕바이러스 항원을 이용한 유행성출혈열 혼합백신 및 혼합진단제
CN120501876A (zh) 一种疫苗保护剂、其制备方法及应用
US20150174236A1 (en) Viral vaccine and process for preparing the same
RU2631129C1 (ru) Способ изготовления вакцины против ящура и вакцина против ящура

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP